Numis Securities Ltd reaffirmed their buy rating on shares of Diurnal Group PLC (LON:DNL) in a research report released on Wednesday. Numis Securities Ltd currently has a GBX 187 ($2.28) target price on the stock.
Shares of Diurnal Group PLC (LON:DNL) opened at 136.00 on Wednesday. Diurnal Group PLC has a 52-week low of GBX 136.00 and a 52-week high of GBX 155.00. The company’s 50-day moving average is GBX 142.03 and its 200 day moving average is GBX 145.46. The firm’s market capitalization is GBX 71.01 million.
About Diurnal Group PLC
Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.
Receive News & Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.